TVTX - Travere Therapeutics, Inc.
28.63
-0.350 -1.222%
Share volume: 868,325
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$28.98
-0.35
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-06-2024 | 08-01-2024 | 10-31-2024 | 02-21-2025 | 05-01-2025 | 08-06-2025 | 10-30-2025 | 02-19-2026 | |
| Assets | |||||||||
| Total Assets | 663.547 M | 551.121 M | 504.410 M | 594.125 M | 548.799 M | 555.309 M | 538.581 M | 605.191 M | |
| Current Assets | 481.076 M | 368.977 M | 324.740 M | 416.702 M | 374.171 M | 379.567 M | 371.110 M | 437.565 M | |
| Inventories | 4.532 M | 5.976 M | 6.356 M | 6.200 M | 3.932 M | 4.090 M | 5.548 M | 5.875 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 397.793 M | 293.105 M | 241.030 M | 312.166 M | 260.345 M | 244.383 M | 143.600 M | 229.761 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 43.251 M | 32.291 M | 36.409 M | 58.535 M | 61.897 M | 75.154 M | 110.930 M | 93.035 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 6.943 M | 6.580 M | 6.162 M | 5.336 M | 4.853 M | 4.561 M | 4.320 M | 4.022 M | |
| Other Assets | 175.528 M | 175.564 M | 173.508 M | 172.087 M | 169.775 M | 171.181 M | 163.151 M | 163.604 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 663.547 M | 551.121 M | 504.410 M | 594.125 M | 548.799 M | 555.309 M | 538.581 M | 605.191 M | |
| Total liabilities | 589.476 M | 535.974 M | 534.864 M | 535.048 M | 515.976 M | 522.562 M | 465.017 M | 490.363 M | |
| Total current liabilities | 173.229 M | 121.268 M | 190.038 M | 200.751 M | 182.457 M | 189.540 M | 135.074 M | 159.904 M | |
| Accounts Payable | 16.725 M | 25.843 M | 23.195 M | 23.534 M | 15.374 M | 19.134 M | 18.225 M | 24.800 M | |
| Other liabilities | 37.666 M | 36.581 M | 34.869 M | 23.987 M | 22.856 M | 22.006 M | 18.573 M | 18.735 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 377.693 M | 378.125 M | 309.957 M | 310.310 M | 310.663 M | 311.016 M | 311.370 M | 311.724 M | |
| Other liabilities | 37.666 M | 36.581 M | 34.869 M | 23.987 M | 22.856 M | 22.006 M | 18.573 M | 18.735 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 74.071 M | 15.147 M | -30.454 M | 59.077 M | 32.823 M | 32.747 M | 73.564 M | 114.828 M | |
| Common stock | 1.338 B | 1.349 B | 1.357 B | 1.506 B | 1.522 B | 1.535 B | 1.550 B | 1.589 B | |
| Retained earnings | -1.262 B | -1.332 B | -1.387 B | -1.447 B | -1.488 B | -1.501 B | -1.475 B | -1.473 B |